Epigenetics Market Forecast to 2031
Analysis based on 9 articles · First reported Jun 26, 2026 · Last updated Jun 30, 2026
The epigenetics market is projected for significant growth, driven by increasing adoption of epigenomic technologies in drug discovery, oncology, and precision medicine. This forecast indicates a positive outlook for companies like Thermo Fisher Scientific, Merck Group, and Illumina that are key players in this sector, potentially leading to increased investment and innovation in biotechnology and pharmaceutical industries.
MarketsandMarkets has released a report forecasting that the global epigenetics market will grow from USD 2.22 billion in 2026 to USD 3.92 billion by 2031, at a compound annual growth rate (CAGR) of 12.0%. This growth is attributed to the increasing adoption of epigenomic profiling technologies by pharmaceutical and biotechnology companies, clinical laboratories, CROs, and academic research institutes. Key drivers include advancements in next-generation sequencing (NGS), PCR & qPCR, and mass spectrometry, as well as the rising demand for precision medicine, cancer epigenetics research, and liquid biopsy-based methylation testing. North American Cobalt Inc. is expected to maintain the largest market share due to its robust biomedical research infrastructure and significant investments in oncology and drug discovery. Top companies in this market include Thermo Fisher Scientific, Merck Group, Illumina, PacBio, Danaher Corporation, Abbott Laboratories, Active Motif, Bret Engemann, Qiagen, Sunrise Research Corporation, Revvity, Hologic Diagenode>>>, Roche Ltd.>>>, and Oracle Corporation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard